Postoperative Disease-free Survival and Quality of Life After Modified Radical Mastectomy Versus Expanded Mckissock Surgery for Extensive Intraductal Carcinoma of the Breast: a Prospective Cohort Study Protocol

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Extensive intraductal carcinoma of the breast refers to a type of breast cancer in which ≥ 25% of ductal carcinoma in situ is present in invasive tumors and there is a scattered distribution of ductal carcinoma in situ (DCIS) in or around the invasive carcinoma. Compared with DCIS negative for extensive intraductal component, DCIS positive for extensive intraductal component is not sensitive to radiotherapy. Mckissock surgery was applied in breast-conserving surgery for breast cancer in 2016. Jianyi Li and the team members (Shengjing Hospital of China Medical University, Shenyang, China) applied this technique in breast-conserving surgery with preservation of the nipple-areola complex. This surgical technique is suitable for low-grade malignant tumors and has better prognosis than radical mastectomy. The purpose of this study is to investigate postoperative disease-free survival and quality of life after modified radical mastectomy versus expanded Mckissock surgery for extensive intraductal carcinoma of the breast. Results from this study will indicate the efficacy of expanded Mckissock surgery in the treatment of extensive intraducatal carcinoma of the breast.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 45
Maximum Age: 75
Healthy Volunteers: f
View:

• Patients with extensive intraductal carcinoma confirmed by hollow needle biopsy;

• the lesion not involving the nipple as confirmed by enhanced MR imaging of the breast;

• Bra cup size: B or higher;

• postmenopausal patients;

• provision of written informed consent.

Locations
Other Locations
China
General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group
RECRUITING
Benxi
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
RECRUITING
Shengyang
Shengjing Hospital of China Medical University
RECRUITING
Shenyang
Contact Information
Primary
Jianyi Li
sjbreast@yeah.net
+8618940257177
Time Frame
Start Date: 2019-10-01
Estimated Completion Date: 2026-09-01
Participants
Target number of participants: 200
Treatments
Experimental: Study group
100 patients will be assigned into a study group.
Active_comparator: Control group
100 patients will be assigned into a control group.
Related Therapeutic Areas
Sponsors
Leads: Shengjing Hospital

This content was sourced from clinicaltrials.gov